Bispecific antibody specifically binding to GPNMB and CD3, and use thereof

Patent metadata

Field	Value
Publication number	US-12319746-B2
Application number	US-202017431218-A
Country	US
Kind code	B2
Filing date	Apr 6, 2020
Priority date	Apr 8, 2019
Publication date	Jun 3, 2025
Grant date	Jun 3, 2025

Abstract

A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.

First claim

The invention claimed is:

1. A bispecific antibody, comprising:
a first domain that specifically binds to GPNMB (glycoprotein non-metastatic melanoma protein B); and
a second domain that specifically binds to CD3 (cluster of differentiation 3),
wherein the first domain comprises
a heavy chain variable region (VH) that comprises
H-CDR1 of the amino acid sequence of SEQ ID NO: 1, 7, 8, 9, 10, or 11;
H-CDR2 of the amino acid sequence of SEQ ID NO: 2; and
H-CDR3 of the amino acid sequence of SEQ ID NO: 3; and

a light chain variable region (VL) that comprises
L-CDR1 of the amino acid sequence of SEQ ID NO: 4;
L-CDR2 of the amino acid sequence of SEQ ID NO: 5 or 12; and
L-CDR3 of the amino acid sequence of SEQ ID NO: 6.

2. The bispecific antibody of claim 1 , wherein the heavy chain variable region and the light chain variable region of the first domain are linked to each other through a linker.

3. The bispecific antibody of claim 2 , wherein the first domain comprises any one amino acid sequence selected from the group consisting of SEQ ID NOs: 19 to 25.

4. The bispecific antibody of claim 1 , wherein the second domain comprises
a heavy chain variable region (VH) that comprises H-CDR1 of the amino acid sequence of SEQ ID NO: 13; H-CDR2 of the amino acid sequence of SEQ ID NO: 14; and H-CDR3 of the amino acid sequence of SEQ ID NO: 15; and
a light chain variable region (VL) that comprises L-CDR1 of the amino acid sequence of SEQ ID NO: 16; L-CDR2 of the amino acid sequence of SEQ ID NO: 17; and L-CDR3 of the amino acid sequence of SEQ ID NO: 18.

5. The anti-GPNMB/anti-CD3 bispecific antibody of claim 4 , wherein the heavy chain variable region and the light chain variable region of the second domain are linked to each other through a linker.

6. The bispecific antibody of claim 5 , wherein the second domain comprises the amino acid sequence of SEQ ID NO: 49 or SEQ ID NO: 51.

7. The bispecific antibody of claim 1 , wherein the first domain and/or the second domain further comprises an Fc region.

8. The bispecific antibody of claim 7 , wherein the Fc region of the first domain and/or the Fc region of the second domain is derived from the heavy chain constant region (CH) of IgG1, IgG2, IgG3, or IgG4.

9. The bispecific antibody of claim 7 , wherein one of the Fc regions in the first domain and the second domain has a knob structure, and the other has a hole structure.

10. The bispecific antibody of claim 7 , wherein the Fc region of the first domain comprises the amino acid sequence of SEQ ID NO: 47 or 48.

11. The bispecific antibody of claim 7 , wherein the Fc region of the second domain comprises the amino acid sequence of SEQ ID NO: 48 or 47.

12. The bispecific antibody of claim 1 , wherein the first domain comprises the amino acid sequence of SEQ ID NO: 34 or 35.

13. The bispecific antibody of claim 1 , wherein the second domain comprises the amino acid sequence of SEQ ID NO: 36, 40, or 41.

14. The bispecific antibody of claim 1 , wherein the bispecific antibody specifically binds to T cells and GPNMB-expressing cancer cells.

15. A polynucleotide selected from the following:
(a) a polynucleotide encoding the first domain of claim 1 ,
(b) a polynucleotide encoding the second domain of claim 1 ,
(c) a polynucleotide encoding the first domain and the second domain of claim 1 , or
(d) a combination of (a) and (b).

16. An expression vector selected from
(a′) an expression vector loaded with the polynucleotide (a) of claim 15 ,
(b′) an expression vector loaded with the polynucleotide (b) of claim 15 ,
(c′) an expression vector loaded with the polynucleotide (c) of claim 15 , or
(d′) a combination of (a′) and (b′).

17. A host cell, transformed with the expression vector of claim 16 .

18. A method for producing an anti-GPNMB/anti-CD3 bispecific antibody, comprising steps of:
expressing the expression vector (c′) or (d′) of claim 16 in a culture; and
isolating the anti-GPNMB/anti-CD3 antibody from the culture.

19. A pharmaceutical composition comprising the bispecific antibody of claim 1 and a pharmaceutically acceptable carrier.

20. A method for treating cancer in a subject, comprising administering, to the subject, an effective amount of the pharmaceutical composition of claim 19 .

21. The method of claim 20 , wherein the cancer expresses GPNMB.

22. The method of claim 21 , wherein the cancer is one or more selected from the group consisting of colorectal cancer, lung cancer, brain cancer, pancreatic cancer, ovarian cancer, breast cancer, prostate cancer, liver cancer, thyroid cancer, head and neck cancer, gastric cancer, bladder cancer, non-Hodgkin's lymphoma, skin cancer, melanoma, leukemia, neuroblastoma, and glioblastoma.

23. The method of claim 20 , wherein the first domain of the anti-GPNMB/anti-CD3 bispecific antibody comprises the amino acid sequence of SEQ ID NO: 34 or 35.

24. The method of claim 20 , wherein the second domain of the anti-GPNMB/anti-CD3 bispecific antibody comprises the amino acid sequence of SEQ ID NO: 36, 40, or 41.

Assignees

• Green Cross Corp
• Mogam Inst Biomedical Res

Inventors

• Park Jae Chan
• Song Eun Jung
• Lim So Jung
• Lee Jae-Chul
• Kwon Hae Naem
• Lee Su A
• Lim Ok Jae
• Kim Mun Kyung
• Cho Hyun Jung
• Kim Gil-Jung
• Lee Jee Won
• Kim Sung Keun
• Won Jong Wha
• Jang Shin A

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K16/2809 Primary

  against the T-cell receptor (TcR)-CD3 complex · CPC title